Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis

Abraham S. Kanate; Alyssa DiGilio; Kwang W. Ahn; Monzr Al Malki; Eric Jacobsen; Amir Steinberg; Nelson Hamerschlak; Mohamed Kharfan-Dabaja; Rachel Salit; Edward Ball; Qaiser Bashir; Amanda Cashen; Daniel Couriel; Jose Diez-Martin; Emmanuel Katsanis; Yulia Linhares; Shahram Mori; Richard Nash; Attaphol Pawarode; Miguel Angel Perales; Colin D. Phipps; Carol Richman; Bipin N. Savani; Michael Y. Shapira; Patrick Stiff; Roger Strair; Timothy S. Fenske; Sonali M. Smith; Anna Sureda; Horatiu Olteanu; Mehdi Hamadani

doi:10.1111/bjh.14879

Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis

Abraham S. Kanate, Alyssa DiGilio, Kwang W. Ahn, Monzr Al Malki, Eric Jacobsen, Amir Steinberg, Nelson Hamerschlak, Mohamed Kharfan-Dabaja, Rachel Salit, Edward Ball, Qaiser Bashir, Amanda Cashen, Daniel Couriel, Jose Diez-Martin, Emmanuel Katsanis, Yulia Linhares, Shahram Mori, Richard Nash, Attaphol Pawarode, Miguel Angel PeralesColin D. Phipps, Carol Richman, Bipin N. Savani, Michael Y. Shapira, Patrick Stiff, Roger Strair, Timothy S. Fenske, Sonali M. Smith, Anna Sureda, Horatiu Olteanu, Mehdi Hamadani

Research output: Contribution to journal › Letter › peer-review

58 Scopus citations

Original language	English
Pages (from-to)	916-920
Number of pages	5
Journal	British Journal of Haematology
Volume	182
Issue number	6
DOIs	https://doi.org/10.1111/bjh.14879
State	Published - Sep 2018

Keywords

allogeneic haematopoietic cell transplantation
extranodal NK/T-cell lymphoma
non-relapse mortality
relapse
survival

Access to Document

10.1111/bjh.14879

Cite this

Kanate, A. S., DiGilio, A., Ahn, K. W., Al Malki, M., Jacobsen, E., Steinberg, A., Hamerschlak, N., Kharfan-Dabaja, M., Salit, R., Ball, E., Bashir, Q., Cashen, A., Couriel, D., Diez-Martin, J., Katsanis, E., Linhares, Y., Mori, S., Nash, R., Pawarode, A., ... Hamadani, M. (2018). Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. British Journal of Haematology, 182(6), 916-920. https://doi.org/10.1111/bjh.14879

@article{5cb6951ff0424d96aa7ee578516e7a07,

title = "Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis",

keywords = "allogeneic haematopoietic cell transplantation, extranodal NK/T-cell lymphoma, non-relapse mortality, relapse, survival",

author = "Kanate, {Abraham S.} and Alyssa DiGilio and Ahn, {Kwang W.} and {Al Malki}, Monzr and Eric Jacobsen and Amir Steinberg and Nelson Hamerschlak and Mohamed Kharfan-Dabaja and Rachel Salit and Edward Ball and Qaiser Bashir and Amanda Cashen and Daniel Couriel and Jose Diez-Martin and Emmanuel Katsanis and Yulia Linhares and Shahram Mori and Richard Nash and Attaphol Pawarode and Perales, {Miguel Angel} and Phipps, {Colin D.} and Carol Richman and Savani, {Bipin N.} and Shapira, {Michael Y.} and Patrick Stiff and Roger Strair and Fenske, {Timothy S.} and Smith, {Sonali M.} and Anna Sureda and Horatiu Olteanu and Mehdi Hamadani",

note = "Funding Information: CIBMTR Support List: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genen-tech, Inc.;*Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children{\textquoteright}s Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick{\textquoteright}s Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *TerumoBCT; *Teva Neuroscience, Inc.; *THERAKOS, Inc.; University of Minnesota; University of Utah; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. *Corporate Members. The authors thank Morgan Geron-ime for administrative support. Funding Information: 1Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA, 2CIBMTR (Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA, 3Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA, 4City of Hope National medical Center, Duarte, CA, USA, 5Dana Farber Cancer Institute, Boston, MA, USA,6Department of Hematology-Oncology, Mount Sinai Hospital, New York, NY, USA,7Albert Einstein Hospital, Sao Paulo, Brazil, 8Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, 9Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 10University of California San Diego Medical Center, La Jolla, CA, USA, 11Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 12Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA, 13Utah Blood and Marrow Transplant Program, Salt Lake City, UT, USA, 14Hospital General Universitario Gregorio Maranon, Madrid, Spain, 15University of Arizona Medical Center, Tucson, AZ, USA, 16Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA, 17Blood & Marrow Transplant Center, Florida Hospital Medical Group, Kissimmee, FL, USA, 18Colorado Blood Cancer Institute, Denver, CO, USA, 19Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI, USA, 20Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, 21Department of Haematology, Singapore General Hospital, Singapore, Singapore, 22University of California Davis Cancer Center, Sacramento, CA, USA, 23Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA, 24Department of Bone Marrow Transplant, Hadassah Medical Centre, Jerusalem, Israel, 25Loyola University Medical Center, Maywood, IL, USA, 26Robert Wood Johnson University Hospital, New Brunswick, NJ, USA, 27Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA,28Section of Hematology/Oncology, The University of Chicago, Chicago, IL, USA, 29Haematology Department, Institut Catala d{\textquoteright}Oncologia - Hospitalet, Barcelona, Spain and 30Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA. E-mail: [email protected] Funding Information: CIBMTR Support List: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.;*Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *TerumoBCT; *Teva Neuroscience, Inc.; *THERAKOS, Inc.; University of Minnesota; University of Utah; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. *Corporate Members. The authors thank Morgan Geronime for administrative support.",

year = "2018",

month = sep,

doi = "10.1111/bjh.14879",

language = "English",

volume = "182",

pages = "916--920",

journal = "British Journal of Haematology",

issn = "0007-1048",

number = "6",

}

Kanate, AS, DiGilio, A, Ahn, KW, Al Malki, M, Jacobsen, E, Steinberg, A, Hamerschlak, N, Kharfan-Dabaja, M, Salit, R, Ball, E, Bashir, Q, Cashen, A, Couriel, D, Diez-Martin, J, Katsanis, E, Linhares, Y, Mori, S, Nash, R, Pawarode, A, Perales, MA, Phipps, CD, Richman, C, Savani, BN, Shapira, MY, Stiff, P, Strair, R, Fenske, TS, Smith, SM, Sureda, A, Olteanu, H & Hamadani, M 2018, 'Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis', British Journal of Haematology, vol. 182, no. 6, pp. 916-920. https://doi.org/10.1111/bjh.14879

TY - JOUR

T1 - Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type

T2 - a CIBMTR analysis

AU - Kanate, Abraham S.

AU - DiGilio, Alyssa

AU - Ahn, Kwang W.

AU - Al Malki, Monzr

AU - Jacobsen, Eric

AU - Steinberg, Amir

AU - Hamerschlak, Nelson

AU - Kharfan-Dabaja, Mohamed

AU - Salit, Rachel

AU - Ball, Edward

AU - Bashir, Qaiser

AU - Cashen, Amanda

AU - Couriel, Daniel

AU - Diez-Martin, Jose

AU - Katsanis, Emmanuel

AU - Linhares, Yulia

AU - Mori, Shahram

AU - Nash, Richard

AU - Pawarode, Attaphol

AU - Perales, Miguel Angel

AU - Phipps, Colin D.

AU - Richman, Carol

AU - Savani, Bipin N.

AU - Shapira, Michael Y.

AU - Stiff, Patrick

AU - Strair, Roger

AU - Fenske, Timothy S.

AU - Smith, Sonali M.

AU - Sureda, Anna

AU - Olteanu, Horatiu

AU - Hamadani, Mehdi

N1 - Funding Information: CIBMTR Support List: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genen-tech, Inc.;*Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children’s Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick’s Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *TerumoBCT; *Teva Neuroscience, Inc.; *THERAKOS, Inc.; University of Minnesota; University of Utah; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. *Corporate Members. The authors thank Morgan Geron-ime for administrative support. Funding Information: 1Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA, 2CIBMTR (Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA, 3Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA, 4City of Hope National medical Center, Duarte, CA, USA, 5Dana Farber Cancer Institute, Boston, MA, USA,6Department of Hematology-Oncology, Mount Sinai Hospital, New York, NY, USA,7Albert Einstein Hospital, Sao Paulo, Brazil, 8Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, 9Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 10University of California San Diego Medical Center, La Jolla, CA, USA, 11Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 12Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA, 13Utah Blood and Marrow Transplant Program, Salt Lake City, UT, USA, 14Hospital General Universitario Gregorio Maranon, Madrid, Spain, 15University of Arizona Medical Center, Tucson, AZ, USA, 16Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA, 17Blood & Marrow Transplant Center, Florida Hospital Medical Group, Kissimmee, FL, USA, 18Colorado Blood Cancer Institute, Denver, CO, USA, 19Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI, USA, 20Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, 21Department of Haematology, Singapore General Hospital, Singapore, Singapore, 22University of California Davis Cancer Center, Sacramento, CA, USA, 23Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA, 24Department of Bone Marrow Transplant, Hadassah Medical Centre, Jerusalem, Israel, 25Loyola University Medical Center, Maywood, IL, USA, 26Robert Wood Johnson University Hospital, New Brunswick, NJ, USA, 27Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA,28Section of Hematology/Oncology, The University of Chicago, Chicago, IL, USA, 29Haematology Department, Institut Catala d’Oncologia - Hospitalet, Barcelona, Spain and 30Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA. E-mail: [email protected] Funding Information: CIBMTR Support List: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.;*Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *TerumoBCT; *Teva Neuroscience, Inc.; *THERAKOS, Inc.; University of Minnesota; University of Utah; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. *Corporate Members. The authors thank Morgan Geronime for administrative support.

PY - 2018/9

Y1 - 2018/9

KW - allogeneic haematopoietic cell transplantation

KW - extranodal NK/T-cell lymphoma

KW - non-relapse mortality

KW - relapse

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85026730456&partnerID=8YFLogxK

U2 - 10.1111/bjh.14879

DO - 10.1111/bjh.14879

M3 - Letter

C2 - 28771676

AN - SCOPUS:85026730456

SN - 0007-1048

VL - 182

SP - 916

EP - 920

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 6

ER -

Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis

Keywords

Access to Document

Other files and links

Cite this